These findings suggest that SRRM2 may be a promising target antigen for novel immunotherapeutic approaches for MM, such as immunoglobulin-based therapies or immune cell therapies, like CAR-T cell therapy. The gene discussed is SRRM2; the disease is Miyoshi myopathy.